Perifériás nociceptin szint Wilson-kórban

Translated title of the contribution: Peripheral nociceptin level in Wilson's disease patients

M. Hantos, K. Tekes, És Szalay Ferenc

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Plasma level of nociceptin, the endogenous agonists of orphaninFQ/OP4 receptor was found to be siginificantly elevated in Wilson's disease patients (14,87 ± 2,44 pg/ml ± SD, p <0,001, n = 21) compared to age-matched healthy controls (9,18 ± 1,63 pg/ml ± SD, n = 25). Wilson's disease is an autosomal recessive disorder caused by mutation of the gene ATP7B leading to toxic copper accumulation mainly in the liver and brain and in other organs such as, kidney and cornea. Measurements were performed by 125I -radioimmunoassay. Neither sex differences nor correlation between plasma nociceptin levels and liver function test results were found in Wilson's disease patients. It is suggested that significantly elevated plasma nociceptin level is due to the inhibition of nociceptin-inactivating Zn-metallopeptidases (aminopeptidase N, endopeptidase 24.15) by the toxic copper levels, as it is known that changing the central Zn atom to Cu results in an approximately 50% inhibition in the activity of these enzymes. The high plasma nociceptin level in Wilson's disease patients may induce significant impairment in nociceptinerg neurotransmission.

Original languageHungarian
Pages (from-to)260-264
Number of pages5
JournalActa Pharmaceutica Hungarica
Volume72
Issue number4
Publication statusPublished - 2002

Fingerprint

Hepatolenticular Degeneration
Poisons
thimet oligopeptidase
Copper
CD13 Antigens
Liver Function Tests
Metalloproteases
Synaptic Transmission
Sex Characteristics
Cornea
Radioimmunoassay
nociceptin
Kidney
Mutation
Liver
Brain
Enzymes
Genes

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Perifériás nociceptin szint Wilson-kórban. / Hantos, M.; Tekes, K.; Ferenc, És Szalay.

In: Acta Pharmaceutica Hungarica, Vol. 72, No. 4, 2002, p. 260-264.

Research output: Contribution to journalArticle

Hantos, M. ; Tekes, K. ; Ferenc, És Szalay. / Perifériás nociceptin szint Wilson-kórban. In: Acta Pharmaceutica Hungarica. 2002 ; Vol. 72, No. 4. pp. 260-264.
@article{ffe32092d3544cd7bf0e406f910590fe,
title = "Perif{\'e}ri{\'a}s nociceptin szint Wilson-k{\'o}rban",
abstract = "Plasma level of nociceptin, the endogenous agonists of orphaninFQ/OP4 receptor was found to be siginificantly elevated in Wilson's disease patients (14,87 ± 2,44 pg/ml ± SD, p <0,001, n = 21) compared to age-matched healthy controls (9,18 ± 1,63 pg/ml ± SD, n = 25). Wilson's disease is an autosomal recessive disorder caused by mutation of the gene ATP7B leading to toxic copper accumulation mainly in the liver and brain and in other organs such as, kidney and cornea. Measurements were performed by 125I -radioimmunoassay. Neither sex differences nor correlation between plasma nociceptin levels and liver function test results were found in Wilson's disease patients. It is suggested that significantly elevated plasma nociceptin level is due to the inhibition of nociceptin-inactivating Zn-metallopeptidases (aminopeptidase N, endopeptidase 24.15) by the toxic copper levels, as it is known that changing the central Zn atom to Cu results in an approximately 50{\%} inhibition in the activity of these enzymes. The high plasma nociceptin level in Wilson's disease patients may induce significant impairment in nociceptinerg neurotransmission.",
author = "M. Hantos and K. Tekes and Ferenc, {{\'E}s Szalay}",
year = "2002",
language = "Hungarian",
volume = "72",
pages = "260--264",
journal = "Acta Pharmaceutica Hungarica",
issn = "0001-6659",
publisher = "Magyar Gyogyszereszeti Tarsasag",
number = "4",

}

TY - JOUR

T1 - Perifériás nociceptin szint Wilson-kórban

AU - Hantos, M.

AU - Tekes, K.

AU - Ferenc, És Szalay

PY - 2002

Y1 - 2002

N2 - Plasma level of nociceptin, the endogenous agonists of orphaninFQ/OP4 receptor was found to be siginificantly elevated in Wilson's disease patients (14,87 ± 2,44 pg/ml ± SD, p <0,001, n = 21) compared to age-matched healthy controls (9,18 ± 1,63 pg/ml ± SD, n = 25). Wilson's disease is an autosomal recessive disorder caused by mutation of the gene ATP7B leading to toxic copper accumulation mainly in the liver and brain and in other organs such as, kidney and cornea. Measurements were performed by 125I -radioimmunoassay. Neither sex differences nor correlation between plasma nociceptin levels and liver function test results were found in Wilson's disease patients. It is suggested that significantly elevated plasma nociceptin level is due to the inhibition of nociceptin-inactivating Zn-metallopeptidases (aminopeptidase N, endopeptidase 24.15) by the toxic copper levels, as it is known that changing the central Zn atom to Cu results in an approximately 50% inhibition in the activity of these enzymes. The high plasma nociceptin level in Wilson's disease patients may induce significant impairment in nociceptinerg neurotransmission.

AB - Plasma level of nociceptin, the endogenous agonists of orphaninFQ/OP4 receptor was found to be siginificantly elevated in Wilson's disease patients (14,87 ± 2,44 pg/ml ± SD, p <0,001, n = 21) compared to age-matched healthy controls (9,18 ± 1,63 pg/ml ± SD, n = 25). Wilson's disease is an autosomal recessive disorder caused by mutation of the gene ATP7B leading to toxic copper accumulation mainly in the liver and brain and in other organs such as, kidney and cornea. Measurements were performed by 125I -radioimmunoassay. Neither sex differences nor correlation between plasma nociceptin levels and liver function test results were found in Wilson's disease patients. It is suggested that significantly elevated plasma nociceptin level is due to the inhibition of nociceptin-inactivating Zn-metallopeptidases (aminopeptidase N, endopeptidase 24.15) by the toxic copper levels, as it is known that changing the central Zn atom to Cu results in an approximately 50% inhibition in the activity of these enzymes. The high plasma nociceptin level in Wilson's disease patients may induce significant impairment in nociceptinerg neurotransmission.

UR - http://www.scopus.com/inward/record.url?scp=0036947999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036947999&partnerID=8YFLogxK

M3 - Article

VL - 72

SP - 260

EP - 264

JO - Acta Pharmaceutica Hungarica

JF - Acta Pharmaceutica Hungarica

SN - 0001-6659

IS - 4

ER -